Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 5/20 | 0.46 |
| ▸ | YTHDC1 | Q96MU7 | 2/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.35 |
| ▸ | CDK2 | P24941 | 2/20 | 0.35 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | TSPO | P30536 | 1/20 | 0.34 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24954186 | 1.00 | CDK1 (0.46) | CDK1YTHDC1ADORA1ADORA2ACCNE1 | |
| SCHEMBL12417531 | 0.80 | CDK1 (0.58) | CDK1YTHDC1ADORA1ADORA2ACCNE1 | |
| SCHEMBL31106949 | 0.80 | CDK1 (0.43) | CDK1YTHDC1ADORA1ADORA2ACCNE1 | |
| SCHEMBL24954144 | 0.80 | CDK1 (0.43) | CDK1YTHDC1ADORA1ADORA2ACCNE1 | |
| SCHEMBL29426225 | 0.77 | CDK1 (0.68) | CDK1YTHDC1ADORA1ADORA2ACCNE1 | |
| SCHEMBL183035 | 0.77 | CDK1 (0.68) | CDK1YTHDC1ADORA1ADORA2ACCNE1 | |
| SCHEMBL381511 | 0.76 | CDK1 (0.40) | CDK1YTHDC1ADORA1ADORA2ACCNE1 | |
| SCHEMBL7289687 | 0.75 | CDK1 (0.51) | CDK1YTHDC1ADORA1ADORA2ACCNE1 | |
| SCHEMBL381898 | 0.75 | CDK1 (0.43) | CDK1YTHDC1ADORA1ADORA2ACCNE1 | |
| SCHEMBL764036 | 0.74 | CDK1 (0.59) | CDK1YTHDC1ADORA1ADORA2ACCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240343729-A1 | IMIDAZOLE ORGANIC COMPOUNDS AND THEIR USE AGAINST INFLAMMATORY BOWEL DISEASE | Benevolentai Cambridge Limited (GB) | 2024-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240343729-A1 | IMIDAZOLE ORGANIC COMPOUNDS AND THEIR USE AGAINST INFLAMMATORY BOWEL DISEASE | SI, SLC10A2, NOS3 | CDK1 2133/4885YTHDC1 4775/4885ADORA1 2488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.